Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $189 | In Stock | |
5 mg | $497 | In Stock | |
10 mg | $797 | In Stock |
Description | Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer. |
In vitro | Ensituximab (NEO-102) is a novel chimeric monoclonal antibody that targets a glycosylated variant of MUC5AC, exhibiting specificity for colorectal and pancreatic cancers. Preclinical data indicate that ensituximab selectively targets MUC5AC-positive tumors while sparing MUC5AC antigen in non-malignant tissues.[2]. |
Alias | NPC-1C, NEO-102, NEO-101 |
Molecular Weight | 150 kDa |
Cas No. | 1092658-06-4 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.